← All trials
NCT04796922
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Dec 20, 2028
- Completion date
- Sep 28, 2031
- First posted
- Mar 15, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 416
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- IncyteLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.